荟萃分析报告了全血细胞计数 (WBCC) 衍生指标（中性粒细胞与淋巴细胞比率 [NLR]、血小板与淋巴细胞比率 [PLR] 和淋巴细胞与单核细胞比率 [LMR]）的相互矛盾的数据和癌症预后。然而，这些证据的强度和质量尚未得到总体量化。对已发表的队列研究荟萃分析中的证据进行分级，这些研究调查了 NLR、PLR 和 LMR 与癌症预后之间的关联。总共包含 224 篇文章的 694 个关联。根据 AMSTAR，219 篇（97.8%）文章被评为中等到高质量。有四个协会有令人信服的证据支持。与此同时，165 个和 164 个关联分别得到了高度暗示性和暗示性证据的支持。在这篇总体综述中，我们总结了有关 WBCC 衍生指标和癌症预后的现有证据。由于研究之间的效应大小方向并不完全一致，需要进一步研究来评估因果关系并提供确凿的证据。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Meta-analyses have reported conflicting data on the whole blood cell count (WBCC) derived indexes (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], and lymphocyte-to-monocyte ratio [LMR]) and cancer prognosis. However, the strength and quality of this evidence has not been quantified in aggregate. To grade the evidence from published meta-analyses of cohort studies that investigated the associations between NLR, PLR, and LMR and cancer prognosis. A total of 694 associations from 224 articles were included. And 219 (97.8%) articles rated as moderate-to-high quality according to AMSTAR. There were four associations supported by convincing evidence. Meanwhile, 165 and 164 associations were supported by highly suggestive and suggestive evidence, respectively. In this umbrella review, we summarized the existing evidence on the WBCC-derived indexes and cancer prognosis. Due to the direction of effect sizes is not completely consistent between studies, further research is needed to assess causality and provide firm evidence.Copyright © 2024 Elsevier B.V. All rights reserved.